The Latest Breaking News from BAX

Due to Baxter International’s underperformance relative to the broader market over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Baxter International is all set to announce its third-quarter results next month, with analysts predicting a double-digit growth in the company's earnings.

Baxter has underperformed the healthcare sector over the past year, and analysts are cautious about the stock’s prospects.

Becton, Dickinson, and Company have recently underperformed in the Nasdaq, but Wall Street analysts are optimistic about the stock’s prospects.

The medtech industry’s long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading.

As Baxter International has underperformed the broader market over the past year, Wall Street analysts remain cautious about the stock's prospects.

Baxter International is poised to release its second-quarter results this month, and analysts are projecting a double-digit earnings growth.

Growth stocks trading at lower P/E ratio than the industry average can be a suitable investment choice. Top picks now could be Cardinal Health (CAH), Baxter International (BAX), and DocuSign (DOCU). Keep reading.

Becton, Dickinson and Company has lagged the S&P 500 recently, but analysts are optimistic about the stock’s prospects.

Despite Baxter International’s relatively underwhelming performance over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Analysts have provided the following ratings for Baxter Intl (NYSE:BAX) within the last quarter: